Zian Yi | Molecular Biology | Best Researcher Award

Published on by Best Achievements

Mr. Zian Yi | Molecular Biology | Best Researcher Award

Mr. Zian Yi, Air Force Medical University, China.

๐Ÿงฌ Mr. Zian Yi is a Masterโ€™s student at Air Force Medical University, specializing in Orthodontics with a research focus on osteogenic differentiation of stem cells. ๐Ÿฆท He has published 4 SCI-indexed papers, 5 Chinese-language papers, and holds 7 invention patents ๐Ÿ‡จ๐Ÿ‡ณ. His pioneering work on Atoh8 gene regulation enhances bone regeneration using ADSCs, advancing bone tissue engineering. ๐Ÿง ๐Ÿ”ฌ Zianโ€™s dedication to innovation and scientific discovery marks him as a rising star in regenerative medicine. ๐ŸŒŸ๐Ÿ“š

Profile

SCOPUS ID

๐ŸŽ“ Early Academic Pursuits

Mr. Zian Yi began a promising academic journey with a focus on dental sciences, ultimately pursuing a masterโ€™s degree in Orthodontics at the Air Force Medical University, China. With a deep-rooted interest in regenerative medicine, Zian concentrated early research on the osteogenic differentiation of stem cells, laying the foundation for a career in cutting-edge oral and cranio-maxillofacial therapies.

๐Ÿ’ผ Professional Endeavors

As a graduate researcher, Zian Yi has been actively involved in three major research projects, including two consultancy collaborations with industry partners. His hands-on experience in laboratory settings and clinical environments exemplifies a well-rounded professional profile within the field of orthodontic biomedical research.

๐Ÿ”ฌ Contributions and Research Focus On Molecular Biology

Mr. Zian Yiโ€™s pivotal research explores how silencing the gene Atoh8 significantly enhances the osteogenic differentiation of adipose-derived stem cells (ADSCs). His work not only elucidates a genetic regulatory pathway but also offers a novel therapeutic approach for bone regeneration, especially relevant for cranio-maxillofacial surgery. In vivo studies have validated the effectiveness of Atoh8-knockdown ADSC sheets in promoting bone repair in animal models.

๐ŸŒ Impact and Influence

With four SCI-indexed publications, five Chinese-language papers, and seven patents, Zian Yiโ€™s contributions are both innovative and impactful. His research has opened new avenues in bone tissue engineering and stem cell therapy, providing significant value to the scientific community and potential clinical applications.

๐Ÿง  Research Skills

Zian exhibits expertise in molecular biology techniques, gene silencing (siRNA), stem cell culture, in vivo animal modeling, and tissue engineering. His ability to translate molecular findings into pre-clinical applications underlines his comprehensive research skill set.

๐Ÿ… Awards and Honors

Zian Yi is a strong contender for the Best Researcher Award in recognition of his scientific achievements, patents, and original research contributions in stem cell-based orthodontic therapies. His work embodies both academic rigor and translational potential.

๐Ÿ›๏ธ Legacy and Future Contributions

Zian Yi aspires to lead transformative research in genetically modulated regenerative therapies, especially for maxillofacial anomalies. His future work aims to integrate gene editing, bioprinting, and biomaterials for personalized bone repair. With a foundation built on scientific integrity and innovation, Zian Yi is set to become a visionary in orthodontic regenerative medicine.

Publications Top Notes

๐Ÿ“„ Title: Initial seizure episodes risk factors identification during hospitalization of ICU patients: A retrospective analysis of the eICU collaborative research database
๐Ÿ‘จโ€๐Ÿ”ฌ Authors: N. Cheng, Zian Yi, Jiayue Wang, Jun Chen, An Gao
๐Ÿ“ฐ Journal: Journal of Clinical Neuroscience
๐Ÿ“… Year: 2025

Yuan Ma | Biochemistry | Best Researcher Award

Published on by Best Achievements

Dr. Yuan Ma | Biochemistry | Best Researcher Award

Dr. Yuan Ma, The Chinese University of Hong Kong ,China.

๐Ÿ”ฌ Dr. MA Yuan (Ph.D.) is a distinguished researcher in nucleic acid-based drug discovery and aptamer-based translational medicine. Currently a Research Assistant Professor at Hong Kong Baptist University, he has contributed extensively to targeted cancer therapies and precision medicine. With 35+ publications, multiple patents, and high-impact grants, his work advances innovative drug development. He also mentors Ph.D. and Masterโ€™s students, shaping the future of pharmaceutical sciences. His groundbreaking research continues to transform therapeutic strategies in oncology and molecular medicine. ๐Ÿ†๐Ÿ”

๐ŸŒŸ Professional Profile

๐ŸŽ“ Early Academic Pursuits

MA Yuan’s academic journey began at the School of Pharmaceutical Sciences, Peking University, where he earned a Bachelor of Science (2009-2013), specializing in organic chemistry, pharmacology, and pharmaceutical analysis. He continued his education at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, completing a Master of Science (2013-2015) with a focus on DNA synthesis, advanced medicinal chemistry, and tumor pharmacology. His Ph.D. (2015-2019) at the same institution delved into nucleic acid chemistry, advanced organic chemistry, and natural pharmaceutical chemistry, culminating in a thesis on the properties, biological activity, and mechanism of novel nucleoside (acid) lipid delivery of single-stranded oligonucleotides under the mentorship of Prof. Zhenjun Yang.

๐Ÿ’ผ Professional Endeavors

Dr. MA Yuan’s professional career spans prestigious institutions. Since 2022, he has been a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University, leading aptamer-based translational research and drug discovery. Previously, he was a Postdoctoral Research Fellow (2020-2022) at the same institution and an Associate Research Fellow (2019-2020) at Mengchao Hepatobiliary Hospital of Fujian Medical University, where he contributed to nucleic acid-based diagnosis and treatment of primary liver cancer.

๐Ÿ”ฌ Contributions and Research Focus On Biochemistryย 

Dr. MA Yuan’s research primarily focuses on aptamer-based drug discovery, nucleic acid chemistry, and translational medicine. His expertise spans nucleic acid-based therapies, precision medicine, and advanced pharmaceutical formulations. He has supervised multiple postgraduate students, contributing to groundbreaking studies in triple-negative breast cancer, ovarian cancer therapy, and osteogenesis imperfecta.

๐ŸŒ Impact and Influence

Through his research, Dr. MA Yuan has secured major research grants exceeding HK$ 51 million from institutions such as the Research Grants Council and the National Natural Science Foundation of China. His work has contributed significantly to novel drug discoveries and advancements in precision medicine. He also holds three patents for innovations in nucleic acid drug delivery and targeted cancer treatments.

๐Ÿ† Awards and Honors

Dr. MA Yuan has received several prestigious awards and recognitions, including Orphan Drug and Rare Pediatric Disease Designations from the FDA for his contributions to osteogenesis imperfecta and gastric cancer treatments.

๐Ÿ“šAcademic Citations

Dr. MA Yuan has authored 35 peer-reviewed publications in esteemed journals, furthering knowledge in nucleic acid chemistry, aptamer-based therapies, and pharmacology. His work has been widely cited, reflecting its impact on biomedical research and pharmaceutical sciences.

  • Machine learning-powered, high-affinity modification strategies for aptamers
    Journal: Acta Materia Medica
    Year: 2025
    ๐Ÿ“š๐Ÿค–

  • Peptide Aptamerโ€“Paclitaxel Conjugates for Tumor Targeted Therapy
    Journal: Pharmaceutics
    Year: 2024
    ๐Ÿ’Š๐ŸŽฏ

  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Journal: Journal of Medicinal Chemistry
    Year: 2024
    ๐Ÿงฌ๐Ÿ’‰

  • Targeting osteoblastic 11ฮฒ-HSD1 to combat high-fat diet-induced bone loss and obesity
    Journal: Nature Communications
    Year: 2024
    ๐Ÿ”๐Ÿฆด

  • Aptamer Functionalized Hypoxia-potentiating Agent and Hypoxia-inducible Factor Inhibitor Combined with Hypoxia-activated Prodrug for Enhanced Tumor Therapy
    Journal: Cancer Letters
    Year: 2024
    Citations: Not Available
    ๐Ÿงฌ๐Ÿฆ 

  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Journal: Journal of Translational Medicine
    Year: 2024
    ๐ŸŽ—๏ธ๐Ÿ’ช

  • Sclerostin inhibition in rare bone diseases
    Journal: Journal of Orthopaedic Translation
    Year: 2024
    ๐Ÿฆต๐Ÿฆด

  • Small RNAs in Cancer Therapy
    Book Chapter: Interdisciplinary Cancer Research
    Year: 2024
    Citations: Not Available
    ๐Ÿ“–๐Ÿงฌ

  • Aptamer AS411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer
    Journal: RSC Medicinal Chemistry
    Year: 2024
    ๐Ÿšฌ๐Ÿ’ช

  • Design and synthesis of nucleotidyl lipids and their application in the targeted delivery of siG12D for pancreatic cancer therapy
    Journal: Biomedicine and Pharmacotherapy
    Year: 2024
    ๐Ÿ๐Ÿ”ฌ

  • Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2024
    ๐Ÿฆด๐Ÿ”ฌ

  • The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates
    Book Chapter: Drug Metabolism and Pharmacokinetics
    Year: 2024
    ๐Ÿ’Š๐Ÿงฌ

  • Intracellular sclerostin plays a vital role in tumor progression and metastasis in triple-negative breast cancer
    Journal: Cancer Research
    Year: 2024
    ๐Ÿง ๐Ÿ”ฌ

  • A bimolecular modification strategy for developing long-lasting bone anabolic aptamer
    Journal: Molecular Therapy – Nucleic Acids
    Year: 2023
    ๐Ÿฆดโœจ